+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

This research aims to better understand the use of felzartamab in adults with primary membranous nephropathy PMN, a kidney condition where autoantibodies damage the kidneys filtering units, causing protein leakage into the urine and potential kidney failure. The study compares the effects of felzartamab, a laboratory-made antibody targeting immune cells, with tacrolimus, a commonly used drug for PMN treatment. Participants will be randomly assigned to receive either intravenous felzartamab infusions or oral tacrolimus tablets during the open-label treatment phase. Those who experience worsening kidney function, increased proteinuria, relapse, or no improvement may receive rescue treatments, including standard immunosuppressive therapy or additional felzartamab doses. The study includes an initial screening period lasting up to 42 days, followed by treatment phases and possible rescue therapy, with some participants followed for up to 156 weeks. Throughout the study, participants will attend up to 23 visits for monitoring and assessments. Researchers will measure how many achieve complete remission of proteinuria after 104 weeks, track kidney function stability, assess fatigue and physical health, and monitor safety and immune responses to felzartamab. Follow-up visits occur every 12 weeks if treatment stops early, ensuring continued evaluation until week 104 or beyond.

Age: 18Years - 80YearsAll GendersPhase 3
114 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of surgical aortic valve replacement SAVR compared to transcatheter aortic valve replacement TAVR in patients with isolated severe, calcific aortic stenosis who have a low risk for surgery. This randomized, controlled, multi-center study aims to show that SAVR is not worse than TAVR by measuring combined outcomes like death, stroke, and rehospitalization one year after the procedure. The study is sponsored by Osaka University and includes long-term follow-up for up to 10 years. Participants will be randomly assigned to receive either SAVR or TAVR using commercially available bioprosthetic valves. SAVR involves surgery with a choice of surgical bioprostheses and access methods based on the surgeons preference. TAVR is performed using devices available in approved Japanese facilities. Follow-up visits occur at hospital discharge, 30 days, and annually for up to 10 years to monitor outcomes and safety. During the study, participants will undergo evaluations including clinical assessments, imaging, and monitoring for events such as death, stroke, rehospitalization, valve function, bleeding, and quality of life, assessed by validated questionnaires. The main outcome is a composite of death from any cause, all stroke, and rehospitalization related to valve or procedure within one year. Safety and valve-related complications will also be tracked throughout the follow-up period. Participation may last up to 15 years, including long-term monitoring after the initial treatment.

All AgesAll GendersPhase Not Applicable
37 locations
R

Actively Recruiting

Researchers are evaluating the overall survival of patients with stage I epithelial ovarian cancer after they have undergone comprehensive staging surgery. This phase III trial compares the outcomes of adjuvant chemotherapy versus observation alone. The study aims to determine whether adding chemotherapy after surgery improves survival in this patient group. Participants will be randomly assigned to one of two groups. One group receives adjuvant chemotherapy, which includes either a combination of paclitaxel and carboplatin or docetaxel and carboplatin, given every three weeks for three to six cycles. Switching between paclitaxel and docetaxel is allowed if adverse events occur. The other group undergoes observation without chemotherapy. During the study, participants will be monitored for overall survival up to 60 months from randomization. Researchers will also assess relapse-free survival within the same timeframe. Evaluations include follow-ups to track disease progression, side effects, and general health. The study ensures participants receive appropriate care and measures outcomes to better understand treatment benefits and risks.

Age: 20Years +FEMALEPhase 3
103 locations
E

Actively Recruiting

This research aims to evaluate an experimental drug called REGN7508 in adults undergoing elective unilateral total knee replacement surgery. The study focuses on how well REGN7508 prevents venous thromboembolism VTE and related conditions after surgery. It also investigates side effects, blood levels of the study drug, and whether the body develops antibodies against the drug, which could affect its action or cause side effects. Participants are randomly assigned to receive one of several treatments intravenous REGN7508, subcutaneous REGN7508 with intravenous placebo, oral apixaban with intravenous placebo, or subcutaneous enoxaparin with intravenous placebo. All treatments are given according to the study protocol. The primary evaluation period lasts through approximately 14 days after surgery. During the study, participants undergo monitoring for VTE events including deep vein thrombosis and pulmonary embolism, bleeding events, and adverse reactions up to about 90 days after surgery. Blood samples are taken to measure drug concentration and antibody formation. The main outcome measured is the incidence of VTE through day 12. Safety and drug activity are closely tracked throughout the study period.

Age: 18Years +All GendersPhase 3
47 locations